DE602005014141D1 - Medikamente zur behandlung oder prävention fibrotischer krankheiten - Google Patents

Medikamente zur behandlung oder prävention fibrotischer krankheiten

Info

Publication number
DE602005014141D1
DE602005014141D1 DE602005014141T DE602005014141T DE602005014141D1 DE 602005014141 D1 DE602005014141 D1 DE 602005014141D1 DE 602005014141 T DE602005014141 T DE 602005014141T DE 602005014141 T DE602005014141 T DE 602005014141T DE 602005014141 D1 DE602005014141 D1 DE 602005014141D1
Authority
DE
Germany
Prior art keywords
medicaments
prevention
treatment
fibrotic diseases
fibrotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602005014141T
Other languages
English (en)
Inventor
John Edward Park
Nveed Chaudhary
Thorsten Lehmann-Lintz
Armin Heckel
Gerald Juergen Roth
Joerg Kley
Trixi Brandl
Georg Dahmann
Matthias Grauert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35809691&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005014141(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of DE602005014141D1 publication Critical patent/DE602005014141D1/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE602005014141T 2004-12-24 2005-12-21 Medikamente zur behandlung oder prävention fibrotischer krankheiten Expired - Fee Related DE602005014141D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04030768 2004-12-24
PCT/EP2005/057006 WO2006067168A1 (en) 2004-12-24 2005-12-21 Medicaments for the treatment or prevention of fibrotic diseases

Publications (1)

Publication Number Publication Date
DE602005014141D1 true DE602005014141D1 (de) 2009-06-04

Family

ID=35809691

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005014141T Expired - Fee Related DE602005014141D1 (de) 2004-12-24 2005-12-21 Medikamente zur behandlung oder prävention fibrotischer krankheiten

Country Status (10)

Country Link
US (2) US20060154939A1 (de)
EP (1) EP1830842B1 (de)
JP (1) JP2008525371A (de)
AR (1) AR052841A1 (de)
AT (1) ATE429221T1 (de)
CA (1) CA2591084A1 (de)
DE (1) DE602005014141D1 (de)
ES (1) ES2326276T3 (de)
TW (1) TW200635595A (de)
WO (1) WO2006067168A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
CA2690569A1 (en) * 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh Indolinone derivatives and their use in treating disease-states such as cancer
PE20110213A1 (es) * 2008-07-29 2011-04-16 Boehringer Ingelheim Int Derivados de indolinona como inhibidores de quinasa
US10450295B2 (en) 2013-08-09 2019-10-22 Acclaim BioMed USA LLC Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis
EP3722291B1 (de) * 2015-12-24 2023-07-19 Respivert Limited Indolinon-verbindungen und deren verwendung zur behandlung von fibrotischen krankheiten
JP7039480B2 (ja) * 2016-03-08 2022-03-22 レスピバート・リミテツド プロテインキナーゼ阻害剤としてのインドール誘導体およびそれらの使用
DK3691620T3 (da) 2017-10-05 2022-10-03 Fulcrum Therapeutics Inc P38-kinaseinhibitor reducerer dux4- og downstream-gen-ekspression til behandling af fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043254A (en) * 1998-04-03 2000-03-28 Boehringer Ingelheim Pharma Kg Indolinones having kinase-inhibiting activity
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
US6319918B1 (en) * 1998-06-04 2001-11-20 Boehringer Ingelheim Pharma Kg Substituted indolinones with kinase inhibitory activity
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
AU2001276934A1 (en) * 2000-07-18 2002-02-05 Joslin Diabetes Center Inc. Methods of modulating fibrosis
DE10117204A1 (de) * 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas

Also Published As

Publication number Publication date
WO2006067168A1 (en) 2006-06-29
US20090048267A1 (en) 2009-02-19
AR052841A1 (es) 2007-04-04
US20060154939A1 (en) 2006-07-13
EP1830842B1 (de) 2009-04-22
EP1830842A1 (de) 2007-09-12
JP2008525371A (ja) 2008-07-17
TW200635595A (en) 2006-10-16
CA2591084A1 (en) 2006-06-29
ATE429221T1 (de) 2009-05-15
ES2326276T3 (es) 2009-10-06

Similar Documents

Publication Publication Date Title
DE602005014145D1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
CY2015024I1 (el) Παραγωγα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602005014141D1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
FI20095600A (fi) Koostumus ihosairauksien hoitoa varten
DE502005003840D1 (de) Anlage zur nichtinvasiven medizinischen behandlung
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602007009877D1 (de) Isosorbid-mononitrat-derivate zur behandlung von darmerkrankungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE602005015434D1 (de) Mittel zur behandlung von psychoneurotischen krankheiten
ATE448228T1 (de) Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten
DE602006010364D1 (de) Pharmazeutikum zur prävention oder behandlung von metabolischer knochenkrankheit
ATE359270T1 (de) Phenyl-piperidin-4-yliden-methyl-benzamidderiva e zur behandlung von schmerz oder magen-darm- erkrankungen
EP1846013A4 (de) Behandlung von hauterkrankungen
GB0407710D0 (en) Treatment of diseases
DE602005014624D1 (de) Verbindungen zur behandlung von krankheiten
DE602005023842D1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee